Summit Securities Group’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10
Closed -$189 1119
2025
Q1
$189 Buy
+10
New +$286 ﹤0.01% 736
2024
Q1
Sell
-2,160
Closed -$199K 516
2023
Q4
$199K Buy
+2,160
New +$220K 0.02% 251
2022
Q4
Sell
-7
Closed -$1K 1176
2022
Q3
$1K Buy
+7
New +$996 ﹤0.01% 878

Other funds holding CDLX

Summit Securities Group's CDLX Position: Q2 2025 in Review

Summit Securities Group sold out of Cardlytics (CDLX) in Q2 2025, closing a stake of 10 shares — an estimated $189 sold.

Summit Securities Group first reported a position in CDLX in Q3 2022 and held it in 3 quarters. The position peaked at $199K in Q4 2023. 89 funds tracked by Wall St. Rank hold CDLX as of Q2 2025.

  • Summit Securities Group reported no remaining Cardlytics position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 10 Cardlytics shares in Q2 2025, an estimated $189.
  • Summit Securities Group first reported a position in Cardlytics in Q3 2022 and held it in 3 quarters.
  • Summit Securities Group's Cardlytics position peaked at $199K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Cardlytics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.